Embryo Stem Cell Researchers In Japan Call For Streamlined Review Process
This article was originally published in PharmAsia News
Executive Summary
A panel on embryonic stem cell research convened by Japan's Council for Science and Technology has advocated elimination of national reviews to accelerate stem cell research in the country. Currently in Japan, an embryo is considered a "life bud" by the administration and requires cautious handling. To obtain permission to conduct research, stem cell researchers must go through a two phase review - first with an ethics committee within the research facility and then a national committee review. The panel calls for a revision so the new guideline will track the International Society for Stem Cell Research, which requires review only from a research facility. (Click here for more-Japanese language
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.